Definium Therapeutics, Inc.
NASDAQ:DFTXBiotechnology
-$0.41 today
- Market cap
- $3.99B
- Beta
- 2.38
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.18
Volume 1.91M
Average 2.67M
DFTX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Definium Therapeutics, Inc.NASDAQ: DFTX
Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q3 FY2026 stock-based compensation of $10.78M rose 85.3% year over year, behind the +117.2% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 11.8% from the prior quarter. Over 3 fiscal years it compounded at +13.6% a year.
Context
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +85.3% toward the trailing-twelve-month pace of +117.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 20.1M USD
- Year-over-year change
- +18.8%
- 4-year CAGR
- -17.2%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.1M | +18.8% |
| FY2024 | 2024-12-31 | 16.91M | +9.2% |
| FY2023 | 2023-12-31 | 15.49M | +13.0% |
| FY2022 | 2022-12-31 | 13.71M | -67.9% |
| FY2021 | 2021-12-31 | 42.72M | — |
Stock-Based Compensation vs competitors
How DFTX compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +117.2% is the highest of 9, against a peer median of -12.5%.
- Over three fiscal years its annual growth of +13.6% compares with a peer median of +53.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $10.98B USD | — | +586.2% | — | |
| LTM Jun 2026 | $96.42M USD | +5.3% | +35.5% | 12.4% | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $38.96M USD | +117.2% | +13.6% | — |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $27.96M USD | -33.3% | +53.3% | — |
| LTM Sep 2026 | $26.2M USD | -19.6% | +5.9% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $21.78M USD | +70.4% | +213.9% | 108.9% |
| LTM Mar 2026 | $7.02M USD | -5.4% | +66.3% | — | |
| LTM Mar 2026 | $1.88M USD | -32.3% | — | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $1.37M USD | — | — | — |
| FY2025 | A$979.92K AUD | +11.1% | -13.3% | 18.0% | |
| LTM Mar 2026 | $125K USD | -78.0% | — | — | |
| Peer median (excluding DFTX) | — | -12.5% | +53.3% | 18.0% | |
Competitors are the stored peer set for DFTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (93.04M) | (56.8M) | (95.73M) | (108.68M) | (183.79M) |
| Depreciation & Amortization | 2.62M | 3.18M | 3.16M | 527K | 0 |
| Deferred Income Tax | (1.16M) | 0 | (2.03M) | 0 | 0 |
| Stock-Based Compensation | 42.72M | 13.71M | 15.49M | 16.91M | 20.1M |
| Change in Working Capital | 1.88M | (3.78M) | 6.28M | (3.34M) | 9.44M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.28M | (2.06M) | 2.03M | (2.13M) | 3.34M |
| Other Working Capital | 598K | (1.73M) | 4.26M | (1.22M) | 6.1M |
| Other Non-Cash Items | 1.16M | (6.45M) | 8.46M | 15.45M | 22.7M |
| Operating Cash Flow | (45.82M) | (50.14M) | (64.37M) | (79.13M) | (131.56M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | (297K) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | (268.36M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 116.75M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (297K) | 0 | 0 | 0 | (151.61M) |
| Debt Repayment | 0 | 0 | 14.16M | 10.86M | 20M |
| Common Stock Issued | 81.92M | 42.3M | 7.53M | 250M | 259.9M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 16.9M | 16.75M | 163K | (7.66M) | (12.63M) |
| Financing Cash Flow | 98.82M | 59.05M | 21.85M | 253.2M | 267.27M |
| Effect of Forex Changes | 742K | (309K) | 79K | (30K) | (7K) |
| Net Change in Cash | 53.45M | 8.6M | (42.44M) | 174.04M | (15.9M) |
| Free Cash Flow | (45.82M) | (50.14M) | (64.37M) | (79.13M) | (131.56M) |
Definium Therapeutics, Inc.
NASDAQ:DFTX
Intrinsic Alpha fair value
Locked
Current Price
$29.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.